Neurocritical Care

, Volume 9, Issue 2, pp 277–283

Warfarin Reversal in Anticoagulant-Associated Intracerebral Hemorrhage

  • Joshua N. Goldstein
  • Jonathan Rosand
  • Lee H. Schwamm
Tell Me Something I Do Not Know

Abstract

Anticoagulant-associated intracerebral hemorrhage (ICH) is a devastating disease, causing death in half of patients and permanent disability in the majority of survivors. The finding that patients often continue bleeding after hospital presentation offers the possibility that emergency warfarin reversal may improve outcomes. As no clinical trials have demonstrated the superiority of any one treatment strategy, various treatment options are available. Intravenous vitamin K is the definitive therapy; however, as monotherapy it can require many hours to take effect. Therefore, it is often considered an adjunct agent. Coagulation factors can be repleted with fresh frozen plasma (FFP), which is widely available and relatively low cost, but can require substantial time to deliver in real-world settings. A number of coagulation factor products collectively termed prothrombin complex concentrates (PCCs) are widely available that can rapidly provide many or all the vitamin K-dependent coagulation factors. Recombinant activated factor VII is used in many centers for this purpose, as it is thought to provide a procoagulant effect that may compensate for the lack of the other critical factors. Until clinical trials demonstrate the superiority of any one means of warfarin reversal, a number of expert guidelines from national organizations are available to help local providers guide therapy. At our institution, we have focused on improving the rapid and reliable delivery of a combination of intravenous vitamin K and FFP, with continued re-dosing until the desired INR lowering is achieved.

Keywords

Cerebral hemorrhage Warfarin Plasma Blood coagulation factors Factor VII 

References

  1. 1.
    Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Dixon AA, Holness RO, Howes WJ, Garner JB. Spontaneous intracerebral haemorrhage: an analysis of factors affecting prognosis. Can J Neurol Sci 1985;12:267–71.PubMedGoogle Scholar
  3. 3.
    Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D, Mayberg M, Tilley B, Zabramski JM, Zuccarello M. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999;30:905–15.PubMedGoogle Scholar
  4. 4.
    Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Gebel JM Jr, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, Spilker J, Tomsick TA, Duldner J, Broderick JP. Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33:2636–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Gebel JM Jr, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, Spilker J, Tomsick TA, Duldner J, Broderick JP. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33:2631–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997;48:921–6.PubMedGoogle Scholar
  8. 8.
    Ardizzone TD, Lu A, Wagner KR, Tang Y, Ran R, Sharp FR. Glutamate receptor blockade attenuates glucose hypermetabolism in perihematomal brain after experimental intracerebral hemorrhage in rat. Stroke 2004;35:2587–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Towfighi A, Greenberg SM, Rosand J. Treatment and prevention of primary intracerebral hemorrhage. Semin Neurol 2005;25:445–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006;5:53–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66:1175–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R. Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 1998;29:1160–6.PubMedGoogle Scholar
  13. 13.
    Fujii Y, Tanaka R, Takeuchi S, Koike T, Minakawa T, Sasaki O. Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg 1994;80:51–7.PubMedGoogle Scholar
  14. 14.
    Mayer SA, Rincon F. Ultra-early hemostatic therapy for acute intracerebral hemorrhage. Semin Hematol 2006;43:S70–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Kaushansky K, Kipps T. Blood anticoagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: Brunton L, Lazo JS, Parker K, editors. Goodman and Gillman’s The Pharmacological basis of therapeutics, 11th ed. Mc Graw-Hill; 2006. pp. 1467–88.Google Scholar
  17. 17.
    Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006;119:607–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007;120:700–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Quinones-Hinojosa A, Gulati M, Singh V, Lawton MT. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus 2003;15:E3.PubMedCrossRefGoogle Scholar
  21. 21.
    Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, Broderick JP, Woo D. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2006;5:197–201.PubMedCrossRefGoogle Scholar
  22. 22.
    Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest 2001;119:22S–38S.PubMedCrossRefGoogle Scholar
  23. 23.
    Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006;54:1231–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745–52.PubMedGoogle Scholar
  25. 25.
    Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007;68:116–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63:1059–64.PubMedGoogle Scholar
  27. 27.
    Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006;67:1272–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006;37:1465–70.PubMedCrossRefGoogle Scholar
  29. 29.
    Sjoblom L, Hardemark HG, Lindgren A, Norrving B, Fahlen M, Samuelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik J. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001;32:2567–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003;89:278–83.PubMedGoogle Scholar
  31. 31.
    Ivascu FA, Howells GA, Junn FS, Bair HA, Bendick PJ, Janczyk RJ. Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality. J Trauma 2005;59:1131–7; discussion 1137–1139.PubMedGoogle Scholar
  32. 32.
    Bair H, Ivascu F, Janczyk R, Nittis T, Bendick P, Howells G. Nurse driven protocol for head injured patients on warfarin. J Trauma Nurs 2005;12:120–6.PubMedGoogle Scholar
  33. 33.
    Ivascu FA, Janczyk RJ, Junn FS, Bair HA, Bendick PJ, Howells GA. Treatment of trauma patients with intracranial hemorrhage on preinjury warfarin. J Trauma 2006;61:318–21.PubMedGoogle Scholar
  34. 34.
    Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis 2007. doi:10.1007/S11239-007-0101-1.
  35. 35.
    Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M. Treatment of warfarin-associated intracerebral hemorrhage: literature review, expert opinion. Mayo Clin Proc 2007;82:82–92.PubMedCrossRefGoogle Scholar
  36. 36.
    Hanslik T, Priseau J. The use of vitamin K in patients on anticoagulant therapy: a practical guide. Am J Cardiovasc Drugs 2004;4:43–55.PubMedCrossRefGoogle Scholar
  37. 37.
    Staudinger T, Locker GJ, Frass M. Management of acquired coagulation disorders in emergency and intensive-care medicine. Semin Thromb Hemost 1996;22:93–104.PubMedGoogle Scholar
  38. 38.
    Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115:145–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral versus intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003;163:2469–73.Google Scholar
  40. 40.
    Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999;159:2721–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Crowther MA, Wilson S. Vitamin K for the treatment of asymptomatic coagulopathy associated with oral anticoagulant therapy. J Thromb Thrombolysis 2003;16:69–72.PubMedCrossRefGoogle Scholar
  42. 42.
    Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002;137:251–4.PubMedGoogle Scholar
  43. 43.
    Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004;181:492–7.PubMedGoogle Scholar
  44. 44.
    Soedirman J, De Bruijn E, Maes R, et al. Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation. Br J Clin Pharmacol 1996;41:517–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Guidelines on oral anticoagulation, 3rd ed. Br J Haematol 1998;101:374–87.Google Scholar
  46. 46.
    Scottish Intercollegiate Guidelines Network. Antithrombotic therapy. A national clinical guideline, 1999;1994.Google Scholar
  47. 47.
    Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001;11:175–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Wjasow C, McNamara R. Anaphylaxis after low dose intravenous vitamin K. J Emerg Med 2003;24:169–72.PubMedCrossRefGoogle Scholar
  49. 49.
    Shields RC, McBane RD, Kuiper JD, Li H, Heit JA. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 2001;76:260–6.PubMedGoogle Scholar
  50. 50.
    Fiore L, Scola M, Cantillon C, et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001;11:175–83.PubMedCrossRefGoogle Scholar
  51. 51.
    Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006;4:1853–63.PubMedCrossRefGoogle Scholar
  52. 52.
    Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006;37:151–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005;2:263–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Ozgonenel B, O’Malley B, Krishen P, Eisenbrey AB. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007;82:1091–4.PubMedCrossRefGoogle Scholar
  55. 55.
    MacLennan S, Williamson L. Risks of fresh frozen plasma and platelets. J Trauma 2006;60:S46–S50.PubMedGoogle Scholar
  56. 56.
    Dzik W, Rao A. Why do physicians request fresh frozen plasma? Transfusion 2004;44:1393–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of hemostasis in critically ill patients. British J Haematol 2004;125:69–73.CrossRefGoogle Scholar
  58. 58.
    Abdel-Wahab OI, Healy B, Dzik W. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006;46:1279–85.PubMedCrossRefGoogle Scholar
  59. 59.
    Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006;126:133–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Duguid J, O’Shaughnessy DF, Atterbury C, Maggs PB, Murphy M, Thomas D, Yates S, Williamson L. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cyrosupernatant. Br J Haematol 2004;126:11–28.CrossRefGoogle Scholar
  61. 61.
    Baglin T, Keeling D, Watson H. Guidelines on oral anticoagulation (warfarin): third edition – 2005 update. Br J Haematol 2006;132:277–85.PubMedCrossRefGoogle Scholar
  62. 62.
    Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477–80.PubMedGoogle Scholar
  63. 63.
    Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007;38:2001–23.PubMedCrossRefGoogle Scholar
  64. 64.
    Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991;28:3–5.PubMedGoogle Scholar
  65. 65.
    Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2003;108:25–30.CrossRefGoogle Scholar
  66. 66.
    Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006;4:967–70.PubMedCrossRefGoogle Scholar
  67. 67.
    Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002;116:619–24.PubMedCrossRefGoogle Scholar
  68. 68.
    Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004;113:371–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000;14:458–61.PubMedCrossRefGoogle Scholar
  70. 70.
    Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992;23:972–7.PubMedGoogle Scholar
  71. 71.
    Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999;45:1113–8; discussion 1118–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Hanley J. Warfarin reversal. J Clin Pathol 2004;57:1132–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Kessler C. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? Intensive Care Med 2002;28(Suppl 2):S228–34.PubMedCrossRefGoogle Scholar
  74. 74.
    Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884–8.PubMedGoogle Scholar
  75. 75.
    Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002;8:CS98–100.PubMedGoogle Scholar
  76. 76.
    Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003;98:737–40.PubMedGoogle Scholar
  77. 77.
    Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14:469–77.PubMedCrossRefGoogle Scholar
  78. 78.
    Hoffman M. Laboratory monitoring of high-dose factor VIIa therapy. Ann Intern Med 2003;139:791.PubMedGoogle Scholar
  79. 79.
    Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007;119:643–51.PubMedCrossRefGoogle Scholar
  80. 80.
    Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2007. doi:10.1016/j.thromres.2007.09.002.
  81. 81.
    Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777–85.PubMedCrossRefGoogle Scholar
  82. 82.
    Mayer S. Large Clinical Trials 1/Abstract 1. 16th European Stroke Conference. 2007.Google Scholar
  83. 83.
    O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W. Recommendations for the management of intracranial haemorrhage—part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006;22:294–316.PubMedCrossRefGoogle Scholar
  85. 85.
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S–33S.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Joshua N. Goldstein
    • 1
  • Jonathan Rosand
    • 2
  • Lee H. Schwamm
    • 2
  1. 1.Department of Emergency MedicineMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Department of NeurologyMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations